BOSTON--(BUSINESS WIRE)--Mar. 14, 2018--
Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing
drugs to improve the survival and quality of life of cancer patients,
today announced that the Company will present at the following investor
The 28th Annual Oppenheimer & Co. Healthcare Conference on Tuesday,
March 20, 2018 at 11:30am in New York City, NY, USA.
The 17th Annual Needham Healthcare Conference on Tuesday, March 27,
2018 at 5:00pm in New York City, NY, USA.
A live webcast of each presentation will be available on the investors
section of the Company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
developing and commercializing drugs to improve the survival and quality
of life of cancer patients. Verastem is currently developing duvelisib,
a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully
met its primary endpoint in a Phase 2 study in indolent Non-Hodgkin
Lymphoma (iNHL) and a Phase 3 clinical trial in patients with chronic
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Verastem has
submitted a New Drug Application (NDA) requesting the full approval of
duvelisib for the treatment of patients with relapsed or refractory
CLL/SLL, and accelerated approval for the treatment of patients with
relapsed or refractory follicular lymphoma (FL). In addition, Verastem
is developing the FAK inhibitor defactinib, which is currently being
evaluated in three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different cancer
types, including pancreatic cancer, ovarian cancer, non-small-cell lung
cancer (NSCLC), and mesothelioma. Verastem’s product candidates seek to
treat cancer by modulating the local tumor microenvironment and
enhancing anti-tumor immunity. For more information, please visit www.verastem.com.
Verastem, Inc. forward-looking statements notice
This press release includes forward-looking statements about Verastem's
strategy, future plans and prospects, including statements regarding the
development and activity of Verastem's investigational product
candidates, including duvelisib and defactinib, and Verastem's PI3K and
FAK programs generally, the structure of our planned and pending
clinical trials, Verastem’s financial guidance and the timeline and
indications for clinical development and regulatory submissions. The
words "anticipate," "believe," "estimate," "expect," "intend," "may,"
"plan," "predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions are intended to
identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Each forward-looking
statement is subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in such
statement. Applicable risks and uncertainties include the risks that
acceptance or approval of the NDA will not occur on the expected
timeframes or at all; that even if data from clinical trials is
positive, regulatory authorities may require additional studies for
approval and the product may not prove to be safe and effective; that
the preclinical testing of Verastem's product candidates and preliminary
or interim data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials; that the full
data from the DUO study will not be consistent with the previously
presented results of the study; that data may not be available when
expected, including for the Phase 3 DUO™ study; that the degree of
market acceptance of product candidates, if approved, may be lower than
expected; that the timing, scope and rate of reimbursement for our
product candidates is uncertain; that there may be competitive
developments affecting our product candidates; that data may not be
available when expected; that enrollment of clinical trials may take
longer than expected; that our product candidates will cause unexpected
safety events or result in an unmanageable safety profile as compared to
their level of efficacy; that duvelisib will be ineffective at treating
patients with lymphoid malignancies; that Verastem will be unable to
successfully initiate or complete the clinical development of its
product candidates; that the development of Verastem's product
candidates will take longer or cost more than planned; that Verastem may
not have sufficient cash to fund its contemplated operations; that
Verastem or Infinity Pharmaceuticals, Inc. (Infinity) will fail to fully
perform under the duvelisib license agreement; that Verastem may be
unable to make additional draws under its debt facility or obtain
adequate financing in the future through product licensing,
co-promotional arrangements, public or private equity, debt financing or
otherwise; that Verastem will not pursue or submit regulatory filings
for its product candidates, including for duvelisib in patients with
CLL/SLL or iNHL; and that Verastem's product candidates will not receive
regulatory approval, become commercially successful products, or result
in new treatment options being offered to patients. Other risks and
uncertainties include those identified under the heading "Risk Factors"
in Verastem's Annual Report on Form 10-K for the year ended December 31,
2017 and in any subsequent filings with the U.S. Securities and Exchange
Commission. The forward-looking statements contained in this press
release reflect Verastem's views as of the date of this release, and
Verastem does not undertake and specifically disclaims any obligation to
update any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180314005131/en/
Source: Verastem, Inc.
Marianne M. Lambertson, 781-292-4273
President, Corporate Communications